JPMorgan Chase & Co. reiterated their hold rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a report published on Wednesday, AnalystRatings.com reports. They currently have a $29.00 price target on the stock.

ALLO has been the subject of several other reports. Canaccord Genuity assumed coverage on shares of Allogene Therapeutics in a research report on Monday, November 4th. They issued a buy rating and a $36.00 price objective for the company. Zacks Investment Research cut shares of Allogene Therapeutics from a buy rating to a hold rating in a research report on Monday, August 12th. William Blair reissued a buy rating on shares of Allogene Therapeutics in a research report on Tuesday, November 5th. BTIG Research assumed coverage on shares of Allogene Therapeutics in a research report on Friday, August 9th. They issued a buy rating and a $37.00 price objective for the company. Finally, ValuEngine raised shares of Allogene Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $36.11.

NASDAQ ALLO traded up $0.88 on Wednesday, reaching $27.32. The company had a trading volume of 577,200 shares, compared to its average volume of 416,218. The stock has a market capitalization of $3.37 billion and a PE ratio of -4.15. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.05. Allogene Therapeutics has a 12 month low of $23.37 and a 12 month high of $33.96. The firm’s 50 day moving average price is $27.85 and its 200 day moving average price is $28.07.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04. On average, research analysts expect that Allogene Therapeutics will post -1.95 EPS for the current year.

In other news, insider Alison Moore sold 48,827 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $32.11, for a total value of $1,567,834.97. 36.50% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Allogene Therapeutics during the 2nd quarter valued at approximately $65,000. State Board of Administration of Florida Retirement System acquired a new position in Allogene Therapeutics during the 2nd quarter valued at approximately $228,000. Swiss National Bank acquired a new position in Allogene Therapeutics during the 2nd quarter valued at approximately $1,214,000. Bainco International Investors increased its stake in Allogene Therapeutics by 0.7% during the 2nd quarter. Bainco International Investors now owns 355,913 shares of the company’s stock valued at $9,556,000 after purchasing an additional 2,500 shares in the last quarter. Finally, BNP Paribas Arbitrage SA acquired a new position in Allogene Therapeutics during the 2nd quarter valued at approximately $92,000. Hedge funds and other institutional investors own 54.48% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Read More: Market Capitalization – What it Means for Investors

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.